Beating the Odds With Triple Sequential Transplants

An interview with Rong-Long Chen, MD, Leader of the Pediatric Cancer Multidisciplinary Team, KFSYSCC

When “Ah-Chih” (a pseudonym) was diagnosed at age 23 with a mediastinal germ-cell tumor—an especially aggressive cancer—he followed every textbook step: surgery, multi-agent chemotherapy, even preventive radiation. One year later his tumor markers soared. Surgeons reopened his chest, yet pathology found no malignancy. Two months after that he developed alarming symptoms: one side of his tongue swelled, speech slurred, the left ear rang, an occipital headache flared, and his eyes felt ready to burst. Imaging showed a new mass at the skull base: metastatic relapse of the original tumor.

A Case Few Centers Would Touch

Although modern therapy cures roughly 95 percent of testicular germ-cell cancers, a handful of patients still relapse and resist treatment. Ah-Chih was one of them. Acting on a friend’s advice, he traveled north to Koo Foundation Sun Yat-Sen Cancer Center and met Rong-Long Chen, MD.

Dr. Chen graduated from the National Taiwan University School of Medicine and later pursued cell-therapy research at Children’s Hospital Los Angeles, focusing on gene transfer and immunotherapy. In 1997 he earned an AACR Young Investigator Award for work on neuroblastoma immunomodulation. Over more than 40 years he has become an authority in pediatric hematology-oncology and stem-cell transplantation.

Citing international data, Dr. Chen noted that salvage rates for cases like Ah-Chih’s hover around 4 percent without high-dose therapy; even one autologous transplant raises survival to only 10 percent, and durable cures are virtually unheard-of.

Through long-standing collaboration with leading global centers, KFSYSCC decided to try a protocol developed at Memorial Sloan Kettering by Darren Feldman, MD: triple sequential autologous stem-cell transplants delivered within two months. No hospital in Taiwan had attempted it. Dr. Chen explained the risks and potential benefits to Ah-Chih and his family. They said yes.

A decade later Ah-Chih remains disease-free.

How the Triple Transplant Works

The regimen administers three cycles of ultra-high-dose chemotherapy strong enough to eradicate residual cancer yet lethal to bone marrow. Previously harvested stem cells are infused after each cycle to restart blood formation. Hitting the tumor three times in rapid succession prevents regrowth and drives cell numbers low enough for the immune system to finish the job.

Results So Far

Since Ah-Chih’s success, KFSYSCC has treated three more patients with relapsed mediastinal germ-cell tumors; two are now cured. Altogether ten high-risk patients have undergone the protocol; five show every sign of permanent remission and a sixth is early in follow-up. The cure rate now tops 60 percent in a group once deemed hopeless.

Why KFSYSCC Can Deliver This Therapy

Triple sequential transplant carries real hazards: intense toxicity, infection risk, the need for large stem-cell yields, and high drug costs. KFSYSCC meets those challenges with:

• A transplant platform in place since 2012 for complex leukemias and solid tumors.

• Pharmacokinetic monitoring by clinical pharmacists to keep drug levels effective yet safe.

• Social-work advocacy that secures funding for costly mobilizing agents.

• A fully integrated team—nursing, nutrition, infectious-disease, pharmacy, pathology, neurology, critical care, rehabilitation, mental health, surgery—coordinated down to the smallest detail.

Frequently Asked Questions

What is a germ-cell tumor?

It originates from primordial germ cells that, during embryonic life, should migrate to the gonads. If they stray, tumors can arise not only in testes or ovaries but also in the brain, sacrococcygeal region, mediastinum, or retroperitoneum.

At what ages and with what symptoms do GCTs appear?

They peak before age 5 and again at puberty. Presentation depends on location—an enlarged painless testis, pelvic pain from an ovarian mass, a visible sacral tumor in newborns, headaches and vision changes for brain lesions, cough and chest pain for mediastinal disease.

Do children ever need triple sequential transplants?

Most pediatric GCTs respond to standard surgery and chemotherapy; only rare, high-risk relapses require such aggressive therapy.

What side-effects accompany the protocol?

High-dose chemo causes nausea, hair loss, mucositis, sore throat, bloating, and infection risk. These effects are intense but usually short-lived.

Will insurance cover it?

Some drugs fall outside Taiwan’s National Health Insurance, but KFSYSCC often secures special-case reimbursement.

Ah-Chih’s story proves that even the toughest germ-cell tumors can be beaten when advanced science, a fearless team, and a patient’s courage align.